UPDATE: Goldman Sachs Raises PT to $33 on Mylan on Agila Specialties Purchase
February 28, 2013 at 11:01 AM EST
In a report published Thursday, Goldman Sachs reiterated its Buy rating on Mylan (NYSE: MYL ) and raised its price target from $32 to $33. Goldman Sachs reported that, “MYL announced a definitive agreement to purchase Agila Specialties, a generics injectable producer from Strides Arcolab, for $1.6 bn in
